Pemvidutide
Also known as ALT-801
Pemvidutide is an investigational dual GLP-1/glucagon receptor agonist studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Early- and mid-stage trials have reported average body-weight reductions along with improvements in liver fat markers, generally without the extended dose titration reported for some comparable agents. It remains in clinical development and has not received regulatory approval. Data are currently limited to trial populations.
Reported benefits
- Associated with meaningful average weight loss in early-phase trials
- May reduce liver fat content
- Once-weekly dosing schedule
- Dual-pathway mechanism targeting appetite and hepatic fat metabolism
How it works
Pemvidutide activates GLP-1 receptors, reducing appetite and slowing gastric emptying, while also engaging glucagon receptors, thought to promote hepatic fat oxidation and energy expenditure. It is engineered with a balanced receptor activity ratio intended to support both weight reduction and liver-fat improvement.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 1.2 mg | once weekly |
| Moderate | 1.8 mg | once weekly |
| High | 2.4 mg | once weekly |
Estimate your dose
Dose estimator
Educational estimate for Pemvidutide, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Pemvidutide. Educational only.
Draw to this mark
36units
= 0.36 mL for a 1.8 mg dose
Concentration
5 mg/mL
Doses per vial
5
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Not established; combination with other incretin-based agents is not supported by published research.
Common protocols
Common questions
What is Pemvidutide used for?
Pemvidutide is an investigational dual GLP-1/glucagon receptor agonist studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Early- and mid-stage trials have reported average body-weight reductions along with improvements in liver fat markers, generally without the extended dose titration reported for some comparable agents. It remains in clinical development and has not received regulatory approval. Data are currently limited to trial populations. Reported benefits include associated with meaningful average weight loss in early-phase trials, may reduce liver fat content, once-weekly dosing schedule.
What is a typical Pemvidutide dose?
Reported ranges run 1.2-2.4 mg. A low protocol is 1.2 mg once weekly, and a high protocol is 2.4 mg once weekly. This is reference information, not a dosing recommendation.
What is the half life of Pemvidutide?
Approximately 5-6 days, consistent with once-weekly dosing. That is what sets the dosing frequency, and it is why the timing guidance is weekly · same day, any time.
How is Pemvidutide administered?
Subcutaneous: into fat, under the skin.
How long is a Pemvidutide cycle?
Continuous use per trial protocols on, followed by Not established outside of trial settings off.
What are the side effects of Pemvidutide?
Reported side effects include nausea, vomiting, and diarrhea, especially during titration, decreased appetite, injection-site reactions, potential increases in heart rate reported in some trials, long-term safety data remain limited. Evidence level for this compound is moderate evidence.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Pemvidutide may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →